Original Article

You have full text access to this OnlineOpen article

Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment

  1. Amelia EB Moore1,*,
  2. Glen M Blake1,
  3. Kathleen A Taylor2,
  4. Asad E Rana2,
  5. Mayme Wong2,
  6. Peiqi Chen2,
  7. Ignac Fogelman1

Article first published online: 14 DEC 2009

DOI: 10.1359/jbmr.091108

Issue

Journal of Bone and Mineral Research

Journal of Bone and Mineral Research

Volume 25, Issue 5, pages 960–967, May 2010

Additional Information

How to Cite

Moore, A. E., Blake, G. M., Taylor, K. A., Rana, A. E., Wong, M., Chen, P. and Fogelman, I. (2010), Assessment of regional changes in skeletal metabolism following 3 and 18 months of teriparatide treatment. J Bone Miner Res, 25: 960–967. doi: 10.1359/jbmr.091108

Author Information

  1. 1

    King's College London, Guy's Campus, London, United Kingdom

  2. 2

    Lilly USA, LLC, Indianapolis, IN, USA

*Osteoporosis Research Unit, 1st Floor, Tower Block, Guy's Hospital, London SE1 9RT, UK.

Publication History

  1. Issue published online: 30 APR 2010
  2. Article first published online: 14 DEC 2009
  3. Accepted manuscript online: 27 JAN 2010 12:00AM EST
  4. Manuscript Accepted: 20 NOV 2009
  5. Manuscript Revised: 30 OCT 2009
  6. Manuscript Received: 1 SEP 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (144K)

References

  • 1
    Lindsay R, Nieves J, Formica C, et al. Randomised, controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997; 350: 550–555.
  • 2
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344: 1434–1441.
  • 3
    Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003; 18: 9–17.
    Direct Link:
  • 4
    Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005; 16: 510–516.
  • 5
    Bilezikian JP. Combination anabolic and antiresorptive therapy for osteoporosis: opening the anabolic window. Curr Osteoporos Rep. 2008; 6: 24–30.
  • 6
    Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; 18: 1932–1941.
    Direct Link:
  • 7
    McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med. 2005; 165: 1762–1768.
  • 8
    Arlot M, Meunier PJ, Boivin G, et al. Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res. 2005; 20: 1244–1253.
    Direct Link:
  • 9
    Chen P, Miller PD, Recker R, et al. Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res. 2007; 22: 1173–1180.
    Direct Link:
  • 10
    Ma YL, Zeng Q, Donley DW, et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21: 855–864.
    Direct Link:
  • 11
    Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res. 2005; 20: 962–970.
    Direct Link:
  • 12
    Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21: 1785–1790.
    Direct Link:
  • 13
    Subramanian G, McAfee JG, Blair RJ, Kallfelz FA, Thomas FD. Technetium-99m-methylene diphosphonate–a superior agent for skeletal imaging: comparison with other technetium complexes. J Nucl Med. 1975; 16: 744–755.
  • 14
    CollierBD, FogelmanI, RosenthallL, eds. Skeletal Nuclear Medicine. St. Louis, MO, USA: Mosby; 1996.
  • 15
    Gnanasegaran G, Cook GJ, Fogelman I. Radionuclide scintigraphy in metabolic bone disease In: RosenCJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Washington, DC, USA: American Society for Bone and Mineral Research; 2008: 166–169.
  • 16
    Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I. Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate. Semin Nucl Med. 2001; 31: 28–49.
  • 17
    Park-Holohan SJ, Blake GM, Fogelman I. Quantitative studies of bone using 18F-fluoride and 99mTc-methylene diphosphonate: evaluation of renal and whole-blood kinetics. Nucl Med Commun. 2001; 22: 1037–1044.
  • 18
    Moore AE, Blake GM, Fogelman I. Validation of a blood-sampling method for the measurement of 99mTc-methylene diphosphonate skeletal plasma clearance. J Nucl Med. 2006; 47: 581–586.
  • 19
    Moore AE, Blake GM, Fogelman I. Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling. J Nucl Med. 2008; 49: 375–382.
  • 20
    WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical report series No. 843, Geneva, Switzerland, 1994.
  • 21
    Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998; 8: 468–489.
  • 22
    Patel R, Blake GM, Rymer J, Fogelman I. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int. 2000; 11: 68–75.
  • 23
    Jonsson L, Ljungberg M, Strand SE. Evaluation of accuracy in activity calculations for the conjugate view method from Monte Carlo simulated scintillation camera images using experimental data in an anthropomorphic phantom. J Nucl Med. 2005; 46: 1679–1686.
  • 24
    Moore AE, Hain SF, Blake GM, Fogelman I. Validation of ultrafiltration as a method of measuring free 99mTc-MDP. J Nucl Med. 2003; 44: 891–897.
  • 25
    Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983; 3: 1–7.
  • 26
    Peters AM. Graphical analysis of dynamic data: the Patlak-Rutland plot. Nucl Med Commun. 1994; 15: 669–672.
  • 27
    Grewal GS, Blake GM. Reference data for 51Cr-EDTA measurements of the glomerular filtration rate derived from live kidney donors. Nucl Med Commun. 2005; 26: 61–65.
  • 28
    Lim GC, Wafa WS, Moses AM. Increased focal uptake of Tc-99m labelled MDP on bone scan suggestive of hyperostosis frontalis interna in a patient being treated with teriparatide. J Bone Mineral Res. 2005; 20 [Suppl 1]: S174.
  • 29
    Sy WM. Bone scan in primary hyperparathyroidism. J Nucl Med. 1974; 15: 1089–1091.
  • 30
    Hain SF, Fogelman I. Nuclear medicine studies in metabolic bone disease. Semin Musculoskelet Radiol. 2002; 6: 323–329.
  • 31
    Nishida H, Kaida H, Ishibashi M, et al. Usefulness of bone uptake ratio of bone scintigraphy in hemodialysis patients. Ann Nucl Med. 2005; 19: 91–94.
  • 32
    Messa C, Goodman WG, Hoh CK, et al. Bone metabolic activity measured with positron emission tomography and [18F]fluoride ion in renal osteodystrophy: correlation with bone histomorphometry. J Clin Endocrinol Metab. 1993; 77: 949–955.
  • 33
    Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978; 19: 270–275.
  • 34
    Brenner W, Bohuslavizki KH, Sieweke N, Tinnemeyer S, Clausen M, Henze E. Quantification of diphosphonate uptake based on conventional bone scanning. Eur J Nucl Med. 1997; 24: 1284–1290.
  • 35
    Scillitani A, Dicembrino F, Chiodini I, et al. Global skeletal uptake of 99mTc-methylene diphosphonate (GSU) in patients affected by endocrine diseases: comparison with biochemical markers of bone turnover. Osteoporos Int. 2002; 13: 829–834.
View Full Article (HTML) Get PDF (144K)